On June 18, 2025, Blueprint Medicines Corp's stockholders elected three directors, approved their executive officers' compensation, and ratified Ernst & Young as auditors for 2025. Election results included 44.7 million votes for Jeffrey W. Albers, 46.7 million for Mark Goldberg, and 47.6 million for John Tsai.